Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer
Open Access
- 7 November 2014
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 15 (11) , 20500-20517
Abstract
Genetic and epigenetic changes in the mitogen activated protein kinase (MAPK) signaling render urothelial cancer a potential target for tyrosine kinase inhibitor (TKI) treatment. However, clinical trials of several TKIs failed to prove efficacy. In this context, we investigated changes in MAPK signaling activity, downstream apoptotic regulators and changes in cell cycle distribution in different urothelial cancer cell lines (UCCs) upon treatment with the multikinase inhibitor sorafenib. None of the classical sorafenib targets (vascular endothelial growth factor receptor 1/-receptor 2, VEGFR1/-R2; platelet-derived growth factor receptor α/-receptor β, PDGFR-α/-β; c-KIT) was expressed at significant levels leaving RAF proteins as its likely molecular target. Low sorafenib concentrations paradoxically increased cell viability, whereas higher concentrations induced G1 arrest and eventually apoptosis. MAPK signaling remained partly active after sorafenib treatment, especially in T24 cells with an oncogenic HRAS mutation. AKT phosphorylation was increased, suggesting compensatory activation of the phosphatidylinositol-3-kinase (PI3K) pathway. Sorafenib regularly down regulated the anti-apoptotic myeloid cell leukemia 1 (Mcl-1) protein, but combinatorial treatment with ABT-737 targeting other B-cell lymphoma 2 (Bcl-2) family proteins did not result in synergistic effects. In summary, efficacy of sorafenib in urothelial cancer cell lines appears hampered by limited effects on MAPK signaling, crosstalk with further cancer pathways and an anti-apoptotic state of UCCs. These observations may account for the lack of efficacy of sorafenib in clinical trials and should be considered more broadly in the development of signaling pathway inhibitors for drug therapy in urothelial carcinoma.Keywords
This publication has 56 references indexed in Scilit:
- Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent processBlood, 2012
- The role of c-FLIP splice variants in urothelial tumoursCell Death & Disease, 2011
- S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder CancerPLOS ONE, 2011
- Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA LevelsCancer Research, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Stimulatory effects of the multi‐kinase inhibitor sorafenib on human bladder cancer cellsBritish Journal of Pharmacology, 2010
- Phase 2 trial of sorafenib in patients with advanced urothelial cancerCancer, 2009
- Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 ActivationClinical Cancer Research, 2008
- Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cellsMolecular Cancer, 2008
- Decreased Fas expression in advanced-stage bladder cancer is not related to p53 statusUrology, 2004